|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
| Although it remains a growing trend, Juval Aviv of Interfor assesses the potentially harmful risks associated with outsourcing and the impact they could have on the pharmaceutical industry
Outsourced manufacturing has continued to grow exponentially over the past 20 years, becoming the standard business model for the pharmaceutical industry. At first, these companies provided access to resources not available internally or to additional resources during peak times. Today, however, outsourced manufacturing is a given. It is estimated that the US market for outsourced manufacturing is growing at the rate of 10 to 12 per cent annually, with many companies even outsourcing sales, data processing and computer operations. Smaller companies couldn’t exist without it and even larger, more established companies have turned to outsourced manufacturing to improve the bottom line.
RISK FROM COUNTERFEITERS
Before outsourcing is even considered, you have to be aware that you will be exposing your supply chain to tremendous risk from counterfeiters. Counterfeiting is a considerable and growing problem for the pharmaceutical industry and a danger to the public. Whether or not you choose to outsource, counterfeiting is a problem for every pharmaceutical company. However, sharing product information with third parties obviously increases the risks dramatically.
It is often incorrectly assumed that counterfeit pharmaceuticals are predominantly a problem for developing countries. However, with soaring healthcare costs and the increasing ease of purchasing pharmaceuticals online without a prescription, the problem is reaching countries with developed drug policies and regulations – including the US and the UK. Internet sales are a particular problem as most of the drugs come from unauthorised secondary wholesalers, selling products from counterfeiting hotspots such as Mexico, China and India. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Juval Aviv holds an MA in Business from Tel Aviv University and is President and CEO of Interfor, Inc. Before founding Interfor, Juval served as an officer in the Israel Defense Force, leading an elite Commando/Intelligence Unit, and was later selected by the Israeli Secret Service (Mossad) to participate in a number of intelligence and special operations in many countries in the late 1960s and 1970s. He has personally solved numerous cases of fraud, illegal short-selling, embezzlement and anti-competitive behaviour. Juval is the author of Staying Safe: The Complete Guide to Protecting Yourself, Your Family, and Your Business, 2004. He has also been a frequent contributor to articles and programmes on US preparedness relative to various forms of terrorism. Additionally, Juval serves as a consultant on counterterrorism for the FOX News Channel and has appeared on ABC’s ‘Nightline’, CNN, MSNBC and in numerous national and international newspapers and magazines. |
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
